Home
Stocks
: Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant
Stocks

: Novavax stock soars more than 20% after COVID-19 vaccine study shows nearly 90% efficacy in U.K., but less against new South African variant

4 years ago No Comments

This post was originally published on this site

Novavax Inc. shares jumped more than 15% in after-hours trading Thursday, after the company revealed results of studies that showed its proposed COVID-19 vaccine is nearly 90% effective overall, but much less effective against a new variant.

Related Posts

About The Author

admin
More from this Author